Myasthenia Gravis - Market Insights, Epidemiology and Market Forecast - 2025

Publisher Name :
Date: 28-Jul-2017
No. of pages: 70
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Myasthenia Gravis - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Myasthenia Gravis for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Myasthenia Gravis . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Myasthenia Gravis for 7 major markets.

The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products. Additionally, the Report highlights the frontrunners, the drivers and barriers for the Myasthenia Gravis market, as well as treatment algorithm, current treatments & advancements are included.The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Myasthenia Gravis , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Myasthenia Gravis for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Myasthenia Gravis 7MM market size is estimated to be USD XX by 2025.The DelveInsight Report will help in enhanced understanding of the Myasthenia Gravis market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

  • Understanding historical and forecasted epidemiological data for Myasthenia Gravis covering 7MM from 2015-2025.

  • Segment level epidemiology and market split for Myasthenia Gravis .

  • The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Myasthenia Gravis .

  • The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Myasthenia Gravis market trends.

  • Thorough market distribution based on market share for Myasthenia Gravis .

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis market.

  • To understand the future market competition in the Myasthenia Gravis market and Insightful review of the key market drivers and barriers.

  • Organize sales and marketing efforts by identifying the best opportunities for Myasthenia Gravis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.

  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.

Myasthenia Gravis - Market Insights, Epidemiology and Market Forecast - 2025

Table of Contents

1. Report Introduction

2. Myasthenia Gravis Market Overview at a Glance
2.1. Total Market Share Distribution of Myasthenia Gravis for 7 MM in 2016
2.2. Total Market Share Distribution of Myasthenia Gravis for 7 MM in 2025

3. Myasthenia Gravis
3.1.1. Overview
3.1.2. Symptoms
3.1.3. Pathophysiology
3.1.4. Staging
3.1.5. Diagnosis
3.1.6. Treatment

4. Epidemiology and Patient Population
4.1.1. United States
4.1.1.1. Diagnosed Cases of Myasthenia Gravis in United States
4.1.2. Germany
4.1.2.1. Diagnosed Cases of Myasthenia Gravis in Germany
4.1.3. France
4.1.3.1. Diagnosed Cases of Myasthenia Gravis in France
4.1.4. Italy
4.1.4.1. Diagnosed Cases of Myasthenia Gravis in Italy
4.1.5. Spain
4.1.5.1. Diagnosed Cases of Myasthenia Gravis in Spain
4.1.6. United Kingdom
4.1.6.1. Diagnosed Cases of Myasthenia Gravis in United Kingdom

5. Treatment Algorithm
5.1.1. Treatment Guidelines/Practices

6. Marketed Drugs for Myasthenia Gravis
6.1. Drug 1: Company A
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
6.1.7. Patent Status
6.2. Drug 2: Company B
6.2.1. Drug Description
6.2.2. Mechanism of Action
6.2.3. Regulatory Milestones
6.2.4. Advantages & Disadvantages
6.2.5. Safety and Efficacy
6.2.6. Product Profile
6.2.7. Patent Status

7. Emerging Therapies
7.1. Drug 3: Company C
7.1.1. Description
7.1.2. Regulatory Milestones
7.1.3. Advantages & Disadvantages
7.1.4. Product Profile
7.1.5. Launch Date
7.1.6. Clinical Development
7.1.7. Clinical Pipeline Activity
7.1.8. Ongoing Trials Information
7.1.9. Clinical Trial by Phase
7.2. Drug 4: Company B
7.2.1. Description
7.2.2. Regulatory Milestones
7.2.3. Advantages & Disadvantages
7.2.4. Product Profile
7.2.5. Launch Date
7.2.6. Clinical Development
7.2.7. Clinical Pipeline Activity
7.2.8. Ongoing Trials Information
7.2.9. Clinical Trial by Phase

8. Overview of Total Myasthenia Gravis Market (2016 & 2025)

9. Myasthenia Gravis : Country-Wise Market Analysis
9.1. United States
9.1.1. Historical Market Size (2015-2016)
9.1.2. Forecasted Market Size (2017-2025)
9.2. Germany Market Size
9.2.1. Historical Market Size (2015-2016)
9.2.2. Forecasted Market Size (2017-2025)
9.3. France Market Size
9.3.1. Historical Market Size (2015-2016)
9.3.2. Forecasted Market Size (2017-2025)
9.4. United Kingdom Market Size
9.4.1. Historical Market Size (2015-2016)
9.4.2. Forecasted Market Size (2017-2025)
9.5. Spain Market Size
9.5.1. Historical Market Size (2015-2016)
9.5.2. Forecasted Market Size (2017-2025)
9.6. Italy Market Size
9.6.1. Historical Market Size (2015-2016)
9.6.2. Forecasted Market Size (2017-2025)
9.7. Japan Market Size
9.7.1. Historical Market Size (2015-2016)
9.7.2. Forecasted Market Size (2017-2025)

10. Market Drivers

11. Market Restraints

12. Appendix

13. Report Methodology

14. Consulting Services

15. Disclaimer

16. About DelveInsight

List of Tables

Table 1: Diagnosed Cases Myasthenia Gravis in United States (2015-2025)
Table 2: Diagnosed Cases Myasthenia Gravis in Germany (2015-2025)
Table 3: Diagnosed Cases Myasthenia Gravis in France (2015-2025)
Table 4: Diagnosed Cases Myasthenia Gravis in United Kingdom (2015-2025)
Table 5: Diagnosed Cases Myasthenia Gravis in Spain (2015-2025)
Table 6: Diagnosed Cases Myasthenia Gravis in Italy (2015-2025)
Table 7: Diagnosed Cases Myasthenia Gravis in Japan (2015-2025)
Table 8: List of Marketed Drugs for Myasthenia Gravis
Table 9: List of Pipeline Phase III Drugs for Myasthenia Gravis
Table 10: Drug 1, Clinical Trials by Zone, 2017
Table 11: Clinical Trials by Trial status, 2017
Table 12: Drug 2, Clinical Trials by Zone, 2017
Table 13: Clinical Trials by Trial status, 2017
Table 14: Drug 3, Clinical Trials by Zone, 2017
Table 15: Clinical Trials by Trial status, 2017
Table 16: United States Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Table 17: Germany Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Table 18: France Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Table 19: United Kingdom Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Table 20: Spain Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Table 21: Italy Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Table 22: Japan Market Size of Myasthenia Gravis in USD, Million (2015-2025)

List of Figures

Figure 1: Diagnosed Cases Myasthenia Gravis in United States (2015-2025)
Figure 2: Diagnosed Cases Myasthenia Gravis in Germany (2015-2025)
Figure 3: Diagnosed Cases Myasthenia Gravis in France (2015-2025)
Figure 4: Diagnosed Cases Myasthenia Gravis in United Kingdom (2015-2025)
Figure 5: Diagnosed Cases Myasthenia Gravis in Spain (2015-2025)
Figure 6: Diagnosed Cases Myasthenia Gravis in Italy (2015-2025)
Figure 7: Diagnosed Cases Myasthenia Gravis in Japan (2015-2025)
Figure 8: List of Marketed Drugs for Myasthenia Gravis
Figure 9: List of Pipeline Phase III Drugs for Myasthenia Gravis
Figure 10: Drug 1, Clinical Trials by Zone (%), 2017
Figure 11: Clinical Trials by Trial status, 2017
Figure 12: Drug 2, Clinical Trials by Zone (%), 2017
Figure 13: Clinical Trials by Trial status, 2017
Figure 14: Drug 3, Clinical Trials by Zone (%), 2017
Figure 15: Clinical Trials by Trial status, 2017
Figure 16: United States Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Figure 17: Germany Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Figure 18: France Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Figure 19: United Kingdom Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Figure 20: Spain Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Figure 21: Italy Market Size of Myasthenia Gravis in USD, Million (2015-2025)
Figure 22: Japan Market Size of Myasthenia Gravis in USD, Million (2015-2025)
  • United States Gabapentin Market Report 2017
    Published: 17-Aug-2017        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Gabapentin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Gabap......
  • Encephalomyelitis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 62
    Encephalomyelitis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H2 2017, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape. Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Amo......
  • Epilepsy - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 420
    Epilepsy - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H2 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and sho......
  • Nicotine Addiction - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 63
    Nicotine Addiction - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H2 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape. Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post......
  • Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 163
    Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2017, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) pipeline landscape. Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that includ......
  • Global Epilepsy Therapeutics Market Research Report 2017
    Published: 16-Aug-2017        Price: US 2900 Onwards        Pages: 107
    In this report, the global Epilepsy Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Epilepsy Therapeutics in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Global Gabapentin Sales Market Report 2017
    Published: 11-Aug-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the global Gabapentin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units) , revenue (Million USD) , market share and growth rate of Gabapentin for these regions, from 2012 to 2022 (forecast) , covering - United States - China - Europe - Japan - So......
  • Global Gabapentin Market Research Report 2017
    Published: 07-Aug-2017        Price: US 2900 Onwards        Pages: 106
    In this report, the global Gabapentin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Gabapentin in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan ......
  • Spasticity - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Spasticity -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Spasticity in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Spasticity. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Spasticity. The report contains the targeted patient populations and the forecast method......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs